COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis.

Takasaki, Kazuki; Tsunenari, Takazumi; Mori, Kazuma; Aochi, Satsuki

Takasaki, Kazuki; Tsunenari, Takazumi; Mori, Kazuma; Aochi, Satsuki.

Takasaki K; Obstetrics and Gynecology, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan frantic_pace_of_dying@yahoo.co.jp.
Tsunenari T; Surgery, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.
Mori K; Internal Medicine, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.
Aochi S; Internal Medicine, Japan Self Defence Forces Sapporo Hospital, Sapporo, Hokkaido, Japan.

BMJ Case Rep ; 14(11)2021 Nov 30.

Article in English | MEDLINE | ID: covidwho-1546479

ABSTRACT

ABSTRACT

A 40-year-old man was admitted to our hospital for COVID-19. He had been treated for essential thrombocythemia (ET). He was diagnosed severe illness of COVID-19, oxygen therapy and dexamethasone were administered. There was a possibility of thromboembolic events in this case, apixaban for prophylaxis was added. With these treatments, the patient has made a good recovery, and he was discharged on hospital day 11. There is no standard strategy for prophylaxis of thrombosis in patients with ET, and apixaban could be a clinical benefit for these patients.

Subject(s)

COVID-19; Thrombocythemia, Essential; Adult; Fibrinolytic Agents/therapeutic use; Humans; Male; Pyrazoles; Pyridones; SARS-CoV-2; Thrombocythemia, Essential/complications; Thrombocythemia, Essential/drug therapy

Keywords

COVID-19; medical management

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Thrombocythemia, Essential Type of study: Case report / Prognostic study Topics: Long Covid Limits: Adult / Humans / Male Language: English Year: 2021 Document Type: Article Affiliation country: Bcr-2021-246700

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google